Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Breast Cancer
42%
Metastatic Breast Cancer
35%
Positron Emission Tomography/computed Tomography (PET/CT)
33%
Tumor
33%
Breast Cancer Patients
32%
Fluoro
30%
Human Epidermal Growth Factor Receptor 2 (HER2)
23%
F-18
23%
Zr-89
22%
Tumor Uptake
22%
Zirconium-89 (89Zr)
20%
Molecular Imaging
19%
Bevacizumab
18%
17-estradiol
17%
Estrogen Receptor
16%
Vascular Endothelial Growth Factor
15%
Biodistribution
15%
Male Breast Cancer
14%
17β-estradiol
14%
PET Imaging
13%
Netherlands
11%
Trastuzumab
11%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (HER2-positive breast cancer)
10%
Patients with Breast Cancer
10%
Metastasis
10%
Glomerular Basement Membrane
9%
Overall Survival
9%
Estrogen Receptor Status
8%
95% Confidence Interval
8%
Heparan Sulfate Proteoglycans
7%
Cancer Program
7%
Pregnant Women
7%
Estrogen Receptor-positive
7%
Immunohistochemistry
7%
Primary Breast Cancer
7%
Breast Cancer Treatment
7%
T-DM1
7%
Fluoroestradiol
7%
Tumor Immunity
7%
Whole-body
7%
89Zr-trastuzumab
7%
Endocrine Therapy
6%
Androgen Receptor
6%
SUVmax
6%
Tumor Tissue
6%
Tracer Uptake
6%
Standardized Uptake Value
6%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
6%
Breast Cancer Subtypes
6%
Tumor-like Lesions
6%
Medicine and Dentistry
Breast Cancer
100%
Polyethylene Terephthalate
41%
Positron Emission Tomography
39%
Metastatic Breast Cancer
36%
Estrogen Receptor
35%
Neoplasm
34%
Diethylstilbestrol
29%
Gamma Urogastrone
23%
Epidermal Growth Factor Receptor 2
20%
Fluorine-18
19%
Tumor
18%
Zirconium 89
16%
Molecular Imaging
16%
Malignant Neoplasm
15%
Male Breast Cancer
14%
Metastatic Carcinoma
14%
Radioactive Tracer
13%
Androgen Receptor
11%
Hormone Therapy
10%
Overall Survival
9%
Cancer Therapy
9%
16alpha Fluoroestradiol F 18
9%
Recurrent Disease
9%
Treatment Response
9%
Receptor Expression
8%
Fluorodeoxyglucose F 18
8%
Diseases
8%
Positron Emission Tomography-Computed Tomography
8%
Biodistribution
8%
Biopsy Technique
8%
Chemotherapy
7%
Immunohistochemistry
7%
Recurrence Risk
7%
Biological Marker
6%
Trastuzumab
6%
Intraductal Carcinoma
6%
Primary Tumor
5%
Sentinel Lymph Node Biopsy
5%
Oncology
5%
Fluorodeoxyglucose
5%
Systemic Therapy
5%
BRCA1
5%
Bevacizumab
5%
Injection
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
50%
Neoplasm
43%
Polyethylene Terephthalate
32%
Metastatic Breast Cancer
19%
Gamma Urogastrone
19%
Estrogen Receptor
17%
Zirconium 89
16%
Epidermal Growth Factor Receptor 2
16%
Biological Marker
15%
Malignant Neoplasm
15%
Bevacizumab
15%
Tracer
15%
Diethylstilbestrol
13%
Biodistribution
12%
Trastuzumab
10%
Fluorine 18
8%
Luminespib
8%
Monoclonal Antibody
7%
Vasculotropin
7%
Chemotherapy Regimens
7%
Vasculotropin A
7%
Clinical Trial
6%
Fluorodeoxyglucose F 18
6%
Endocrine Therapy
6%
16alpha Fluoroestradiol F 18
5%
Ovary Cancer
5%
Drug Development
5%
Hormone Receptor
5%
Diseases
5%
Overall Survival
5%
Paclitaxel
5%
Anticarcinogen
5%
Transforming Growth Factor Beta
5%
